Arena Pharmaceuticals, Inc. (ARNA): Price and Financial Metrics
ARNA Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for ARNA is 0 -- better than only 7.95% of US stocks.
- ARNA's price/sales ratio is 15,034.49; that's higher than the P/S ratio of 99.79% of US stocks.
- Revenue growth over the past 12 months for Arena Pharmaceuticals Inc comes in at -99.96%, a number that bests just 0.5% of the US stocks we're tracking.
- Stocks that are quantitatively similar to ARNA, based on their financial statements, market capitalization, and price volatility, are CYAD, CRSP, BLU, ATOM, and GENE.
- Visit ARNA's SEC page to see the company's official filings. To visit the company's web site, go to www.arenapharm.com.
ARNA Stock Price Chart Interactive Chart >
ARNA Price/Volume Stats
| Current price | $79.50 | 52-week high | $90.19 |
| Prev. close | $79.49 | 52-week low | $32.95 |
| Day low | $78.31 | Volume | 11,221 |
| Day high | $81.37 | Avg. volume | 460,282 |
| 50-day MA | $78.04 | Dividend yield | N/A |
| 200-day MA | $70.60 | Market Cap | 4.80B |
Arena Pharmaceuticals, Inc. (ARNA) Company Bio
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing drugs to address unmet medical needs. The company was founded in 1997 and is based in San Diego, California.
Latest ARNA News From Around the Web
Below are the latest news stories about Arena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARNA as an investment opportunity.
Arena Pharmaceuticals Inc.'s (ARNA) CEO Amit Munshi on Q4 2020 Results - Earnings Call TranscriptArena Pharmaceuticals, Inc. (ARNA) Q4 2020 Earnings Conference Call February 23, 2021, 04:30 PM ET Company Participants Patrick Malloy - Vice President, Investor Relations and Corporate Communications Amit Munshi - President and Chief Executive Officer Laurie Stelzer - Executive Vice President and Chief Financial Officer Conference Call Participants Alethia Young... |
Arena Posts Worse-Than-Feared Quarterly Loss As Sales DisappointArena Pharmaceuticals posted a wider-than-expected loss in the fourth quarter, as the biopharmaceutical company’s sales were almost negligible. Shares declined about 2.7% to close at $76.56 on Feb. 23. However, Arena (ARNA) achieved a strong liquidity position and maintained pipeline progress. The company incurred a loss of $2.10 per share in 4Q, compared to the $1.85 loss per share estimated by analysts. Total sales generated in the quarter amounted to $37,000, falling short of analysts’ expectations of $560,000. Arena’s research and development (R&D) expenses came in at $100.4 million in the quarter, up 34.6% year-over-year. Selling, general and administrative (SG&A) expenses were $34.9 million, up 57.2%. Arena CEO Amit D. |
Arena Pharmaceuticals Inc (ARNA) Q4 2020 Earnings Call TranscriptImage source: The Motley Fool. Arena Pharmaceuticals Inc (NASDAQ: ARNA)Q4 2020 Earnings CallFeb 23, 2021, 4:30 p.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day everyone, and welcome to Arena Pharmaceuticals Corporate Conference Call. |
Arena Pharmaceuticals EPS misses by $0.27Arena Pharmaceuticals (ARNA): Q4 GAAP EPS of -$2.10 misses by $0.27.Strong cash position of $1.1 billion as of December 31, 2020Press Release... |
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021, the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to purchase an aggregate of 33,885 shares of its common stock and 8,475 inducement restricted stock units ("RSUs"). The inducement stock options and RSUs have a grant date and vesting commencement date of February 15, 2021 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). |
ARNA Price Returns
| 1-mo | 6.45% |
| 3-mo | 20.64% |
| 6-mo | 12.96% |
| 1-year | 80.27% |
| 3-year | 110.48% |
| 5-year | 419.61% |
| YTD | 3.48% |
| 2020 | 69.15% |
| 2019 | 16.61% |
| 2018 | 14.66% |
| 2017 | 139.23% |
| 2016 | -25.26% |
Continue Researching ARNA
Want to see what other sources are saying about Arena Pharmaceuticals Inc's financials and stock price? Try the links below:Arena Pharmaceuticals Inc (ARNA) Stock Price | Nasdaq
Arena Pharmaceuticals Inc (ARNA) Stock Quote, History and News - Yahoo Finance
Arena Pharmaceuticals Inc (ARNA) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...